HOUSTON, TEXAS — March 2, 2026 — Leads & Copy — Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) has announced that its AI Nose platform is moving from the pilot stage to structured industrial deployment.
According to a letter issued by Chairman, President, and Chief Executive Officer Eddy Tsai to shareholders, the company is emphasizing the recurring revenue potential of deploying up to 20,000 AI Nose systems.
The initial confirmed order for 1,400 AI Nose systems is expected to generate approximately $2.1 million in recurring subscription revenue over a three-year service structure. The company sees this milestone as a transition from proof-of-concept validation to revenue-generating implementation within semiconductor manufacturing environments.
Ainos, Inc. anticipates a phased deployment of up to 20,000 AI Nose systems across customer facilities, potentially supporting annual order values approaching $10 million if fully executed. The progression into subsequent phases will depend on staged technical validation and formal contractual conversion with their customer.
The company is developing AI Nose into a scent intelligence platform with scalability across industries, including healthcare and industrials. The platform’s commercial architecture integrates hardware deployment, subscription-based analytics and monitoring, continuous AI model optimization, and multi-site scalability.
Ainos, Inc. reports that AI Nose is undergoing validation testing within advanced semiconductor front-end fabrication facilities. Successful validation could expand integration opportunities within capital-intensive wafer fabrication environments.
The company’s focus remains on disciplined execution, subscription activation, and scalable infrastructure expansion as it positions scent as the next AI token. This involves advancing the smell language model (SLM), strengthening Smell ID libraries, and building SmellTech, powered by AI Nose, as a foundational sensing infrastructure for industrial AI systems.
Ainos, Inc. is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform digitizes scent into Smell ID, a machine-readable data format. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases.
About AI Nose: AI Nose digitizes scent into Smell ID, integrating MEMS sensor arrays with proprietary AI algorithms to support scent detection sensitivity. Smell ID converts analog scent signals into actionable data, and the Smell Language Model (SLM) is designed to classify and contextualize complex scent patterns. AI Nose is offered under a SmellTech-as-a-Service architecture.
Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Source: Ainos, Inc.
